MCID: CNN010
MIFTS: 32

Connective Tissue Benign Neoplasm malady

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Benign Neoplasm

Aliases & Descriptions for Connective Tissue Benign Neoplasm:

Name: Connective Tissue Benign Neoplasm 12 14
Soft Tissue Neoplasms 42 69
Soft Tissue Benign Neoplasm 12
Neoplasm of Soft Tissues 12
Tumor of the Soft Tissue 12
Neoplasm of Soft Tissue 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060123
MeSH 42 D012983
NCIt 47 C3377
SNOMED-CT 64 126600002 387837005
UMLS 69 C0037579

Summaries for Connective Tissue Benign Neoplasm

Disease Ontology : 12 A musculoskeletal system benign neoplasm that is located in connective tissue.

MalaCards based summary : Connective Tissue Benign Neoplasm, also known as soft tissue neoplasms, is related to gastrointestinal stromal tumor and bone benign neoplasm. An important gene associated with Connective Tissue Benign Neoplasm is MDM2 (MDM2 Proto-Oncogene). The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include connective tissue, and related phenotypes are behavior/neurological and integument

Related Diseases for Connective Tissue Benign Neoplasm

Diseases in the Connective Tissue Cancer family:

Connective Tissue Benign Neoplasm

Diseases related to Connective Tissue Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Related Disease Score Top Affiliating Genes
1 gastrointestinal stromal tumor 29.5 ENO2 PDGFRB SYP
2 bone benign neoplasm 10.9
3 infantile myofibromatosis 10.9
4 glomangiosarcoma 10.8
5 kallmann syndrome 6 10.2 MDM2 RASAL1
6 urinary tract obstruction 10.2 ENO2 MDM2
7 cerebral arterial disease 10.2 ENO2 MDM2
8 aneurysm of sinus of valsalva 10.2 MDM2 SYP
9 pinta disease 10.2 ENO2 MDM2
10 infiltrating renal pelvis transitional cell carcinoma 10.2 ENO2 SYP
11 thymus small cell carcinoma 10.2 ENO2 SYP
12 skeletal-extraskeletal angiomatosis 10.2 ENO2 SYP
13 prolactin producing pituitary tumor 10.2 ENO2 SYP
14 glomus tumor 10.2 ENO2 SYP
15 pemphigus foliaceus 10.2 ENO2 SYP
16 spasmodic dysphonia 10.2 ENO2 SYP
17 autosomal recessive stickler syndrome 10.2 ENO2 SYP
18 ampullary signet ring cell adenocarcinoma 10.2 ENO2 SYP
19 nephrogenic adenoma of urinary bladder 10.2 ENO2 SYP
20 perineural angioma 10.2 ENO2 SYP
21 blood group incompatibility 10.2 ENO2 SYP
22 gliofibroma 10.2 ENO2 SYP
23 adenosarcoma 10.1 ENO2 MDM2 PDGFRB
24 rectum leiomyoma 10.1 ENO2 SYP
25 superior vena cava syndrome 10.1 ENO2 SYP
26 fragile x-associated tremor/ataxia syndrome 10.1 ENO2 SYP
27 gallbladder pleomorphic giant cell adenocarcinoma 10.1 ENO2 SYP
28 adult epithelioid sarcoma 10.1 ENO2 SYP
29 piussan lenaerts mathieu syndrome 10.1 ENO2 SYP
30 thymoma 10.1 ENO2 SYP
31 anal squamous cell carcinoma 10.1 ENO2 SYP
32 small intestinal sarcoma 10.1 ENO2 MDM2
33 uterine corpus myxoid leiomyosarcoma 10.1 ENO2 SYP
34 microsporidiosis 10.1 ENO2 SYP
35 pediculus humanus corporis infestation 10.1 ENO2 SYP
36 childhood central nervous system primitive neuroectodermal neoplasm 10.1 ENO2 MDM2 SYP
37 thoracic outlet syndrome 10.1 ENO2 MDM2 SYP
38 hunter macpherson syndrome 10.1 ENO2 SYP
39 t-cell childhood lymphoblastic lymphoma 10.1 CARMIL2 NDRG4 PDGFRB
40 glucose-6-phosphate translocase deficiency 10.1 MDM2 NDRG4 PDGFRB
41 grade iii astrocytoma 10.1 MDM2 PDGFRB SYP
42 rh isoimmunization 10.1 ENO2 SYP
43 vestibular gland benign neoplasm 10.0 CDC73 GNAS SYP
44 vulvar alveolar soft part sarcoma 10.0 ENO2 SYP
45 brain oligodendroglioma 10.0 MDM2 SYP
46 congenital muscular dystrophy with hyperlaxity 10.0 ENO2 SYP
47 hemangiopericytoma, malignant 10.0
48 kala-azar 1 9.9 ENO2 MDM2 PDGFRB SYP
49 ampulla of vater mucinous adenocarcinoma 9.9 ENO2 SYP
50 secondary lacrimal atrophy 9.9 CDC73 ERCC6 GNAS MDM2 RASAL1

Graphical network of the top 20 diseases related to Connective Tissue Benign Neoplasm:



Diseases related to Connective Tissue Benign Neoplasm

Symptoms & Phenotypes for Connective Tissue Benign Neoplasm

MGI Mouse Phenotypes related to Connective Tissue Benign Neoplasm:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 GNAS MDM2 NDRG4 PDGFRB SYP CARMIL2
2 integument MP:0010771 9.7 ERCC6 GNAS KDM7A MDM2 PDGFRB CARMIL2
3 limbs/digits/tail MP:0005371 9.35 ERCC6 GNAS KDM7A MDM2 PDGFRB
4 nervous system MP:0003631 9.23 ERCC6 GNAS MDM2 NDRG4 PDGFRB SYP

Drugs & Therapeutics for Connective Tissue Benign Neoplasm

Drugs for Connective Tissue Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 740)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Desogestrel Approved Phase 4 54024-22-5 40973
4 Dienogest Approved Phase 4 65928-58-7
5
Goserelin Approved Phase 4,Phase 3 65807-02-5 47725 5311128
6
Nandrolone Approved, Experimental, Illicit Phase 4 434-22-0, 62-90-8 9904 229455
7
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
8
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 341031-54-7, 557795-19-4 5329102
9
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
10
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
11
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
12
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
13
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
14
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
15
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
16
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
17
Calcium carbonate Approved Phase 4,Phase 3 471-34-1
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
19
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
20
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
21
Octreotide Approved, Investigational Phase 4,Phase 2,Phase 1 83150-76-9 383414 6400441
22
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
23
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
24
Nevirapine Approved Phase 4 129618-40-2 4463
25
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
26
Ethanol Approved Phase 4,Phase 1,Phase 2,Early Phase 1 64-17-5 702
27
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
28
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
29
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
30
Tenofovir Approved, Investigational Phase 4,Phase 3 147127-20-6 464205
31
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
32
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
33
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
34
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
35
Zinc oxide Approved Phase 4,Phase 2 1314-13-2
36
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
37
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
38
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
39
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
40
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
41
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 57-83-0 5994
42
Misoprostol Approved Phase 4,Phase 3,Phase 2 59122-46-2 5282381
43
Letrozole Approved, Investigational Phase 4,Phase 2,Phase 1 112809-51-5 3902
44
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 1 169590-42-5 2662
45
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
46
Cetuximab Approved Phase 4,Phase 2,Phase 1 205923-56-4 56842117 2333
47
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
48
Tranexamic Acid Approved Phase 4,Early Phase 1 1197-18-8 5526
49
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
50
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569

Interventional clinical trials:

(show top 50) (show all 2130)
id Name Status NCT ID Phase
1 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
2 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4
3 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4
4 The Hysteroscopic Morcellator (HM). Unknown status NCT01537822 Phase 4
5 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
6 MyoSure Hysteroscopic Tissue Removal System Registry Study Unknown status NCT01369758 Phase 4
7 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4
8 SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery Completed NCT00531739 Phase 4
9 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4
10 Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor Completed NCT00793871 Phase 4
11 Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate Completed NCT00510354 Phase 4
12 Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) Completed NCT00171977 Phase 4
13 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4
14 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
15 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4
16 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
17 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
18 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4
19 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4
20 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4
21 Doxycycline In Lymphangioleiomyomatosis (LAM) Completed NCT00989742 Phase 4
22 Imatinib in KIT-negative Systemic Mastocytosis Completed NCT01297777 Phase 4
23 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
24 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4
25 Fibroids in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4
26 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization Completed NCT02293447 Phase 4
27 Safety Study of ExAblate for the Treatment of Uterine Fibroids Completed NCT01142791 Phase 4
28 Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future Completed NCT00180739 Phase 4
29 MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids Completed NCT00166270 Phase 4
30 Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids Completed NCT00159328 Phase 4
31 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4
32 Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery Completed NCT01388907 Phase 4
33 Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis Completed NCT01217125 Phase 4
34 Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM Recruiting NCT03127072 Phase 4
35 The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Recruiting NCT01427400 Phase 4
36 Sitagliptin and Brown Adipose Tissue Recruiting NCT02294084 Phase 4
37 The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib Recruiting NCT02800330 Phase 4
38 Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas Recruiting NCT02361905 Phase 4
39 Ulipristal Use in Chinese Population Recruiting NCT02825719 Phase 4
40 Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation Recruiting NCT02357563 Phase 4
41 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
42 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Recruiting NCT02361879 Phase 4
43 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4
44 Misoprostol for Reduction of Blood Loss During Fibroid Surgery Recruiting NCT02209545 Phase 4
45 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Recruiting NCT01793584 Phase 4
46 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
47 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Active, not recruiting NCT00756509 Phase 4
48 Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura. Active, not recruiting NCT01694654 Phase 4
49 Uterine Leiomyoma Treatment With Radiofrequency Ablation Active, not recruiting NCT01840124 Phase 4
50 The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids. Active, not recruiting NCT00995878 Phase 4

Search NIH Clinical Center for Connective Tissue Benign Neoplasm

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: soft tissue neoplasms

Genetic Tests for Connective Tissue Benign Neoplasm

Anatomical Context for Connective Tissue Benign Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Connective Tissue Benign Neoplasm:

18
Connective Tissue

Publications for Connective Tissue Benign Neoplasm

Variations for Connective Tissue Benign Neoplasm

Copy number variations for Connective Tissue Benign Neoplasm from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13803 1 1 56100000 Amplification Soft tissue tumor
2 21057 1 156500000 172900000 Amplification Soft tissue tumor
3 151970 20 27500000 41700000 Amplification Soft tissue tumor
4 178515 3 74200000 91000000 Amplification Soft tissue tumor
5 206336 6 139000000 161000000 Amplification Soft tissue tumor

Expression for Connective Tissue Benign Neoplasm

Search GEO for disease gene expression data for Connective Tissue Benign Neoplasm.

Pathways for Connective Tissue Benign Neoplasm

GO Terms for Connective Tissue Benign Neoplasm

Biological processes related to Connective Tissue Benign Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular response to organic substance GO:0071310 8.96 MDM2 SYP
2 response to toxic substance GO:0009636 8.8 ERCC6 MDM2 PDGFRB

Sources for Connective Tissue Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....